<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The plasminogen activator inhibitor-1 (PAI-1) is expressed in many <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell types and allows the modulation of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> growth, invasion and <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> </plain></SENT>
<SENT sid="1" pm="."><plain>To date, studies investigated the association between a functional polymorphism in PAI-1 (4G/5G) and risk of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> have shown inclusive results </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: A meta-analysis based on 25 case-control studies was performed to address this issue </plain></SENT>
<SENT sid="3" pm="."><plain>Odds ratios (OR) with corresponding 95% confidence intervals (CIs) were used to assess the association </plain></SENT>
<SENT sid="4" pm="."><plain>The statistical <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> across studies was examined with I(2) test </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Overall, a significant increased risk of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> was associated with the PAI-1 4G/4G polymorphism for the allele contrast (4G vs. 5G: OR = 1.10, CI��= 1.03-1.18, I(2) = 49.5%), the additive genetic model (4G/4G vs. 5G/5G: OR = 1.21, CI = 1.06-1.39, I(2) = 51.9%), the recessive genetic model (4G/4G vs. 4G/5G+5G/5G: OR = 1.11, CI = 1.04-1.18, I(2) = 20.8%) </plain></SENT>
<SENT sid="6" pm="."><plain>In the subgroup analysis by ethnicity, the results indicated that individuals with 4G/4G genotype had a significantly higher <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risk among Caucasians (4G/4G vs. 5G/5G: OR = 1.31, 95%CI = 1.09-1.59, I(2) = 59.6%; 4G/4G vs. 4G/5G: OR = 1.12, 95%CI = 1.04-1.21, I(2) = 3.6%; recessive model: OR = 1.12, 95%CI = 1.05-1.21, I(2) = 25.3%) </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: The results of the present meta-analysis support an association between the PAI-1 4G/5G polymorphism and increasing <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risk, especially among Caucasians, and those with 4G allele have a high risk to develop <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> and <z:e sem="disease" ids="C0476089" disease_type="Neoplastic Process" abbrv="">endometrial cancer</z:e> </plain></SENT>
</text></document>